Novo Nordisk’s Victoza (liraglutide) Receives FDA’s Approval for Type 2 Diabetes in Children and Adolescents

Novo Nordisk’s Victoza (liraglutide) Receives FDA’s Approval for Type 2 Diabetes in Children and Adolescents

Shots:

  • The approval is based on P-III ELLIPSE study results assessing Victoza (liraglutide, 1.8 mg/day) injection vs PBO + metformin with/without basal insulin in 135 children & adolescents in a ratio (1:1) with T2d aged 10-17yrs.
  • Victoza is providing a new treatment option beyond metformin & insulin for the first time in the last 19 yrs. to lower blood sugar level along with diet & exercise
  • Victoza is GLP-1 receptor agonist and has received the US FDA’s approval as an adjunct to diet and exercise to improve glycemic control in adults with T2D and reduces the risk of CV events in T2D patients with heart disease

Click here to read full press release/ article | Ref: PRNewsWire | Image: Everyday Diabetes